Apex Medical / Market Entry
Clearance is permission. It isn't a market.
A licence gives you the legal right to sell. It does not give you a route to market, a price a hospital will accept, access to the people who decide, or anyone with a reason to change what they already use. That second list is the business — and it is what Apex builds.
The distinction that decides the year
Two paths run in parallel. Only one of them ends in revenue.
Most companies resource the first path properly and improvise the second. Both take months. Only one has a stop at the end of it.
Regulatory entry
Legal permission to sell
- Classification and pathway determination
- Submission — Health Canada licence or FDA clearance
- Review and questions
- Establishment licensing (MDEL) and quality systems
- Licence granted
Permission to sell.The path ends here. Nothing about it creates demand, a price or a buyer.
Commercial entry — Apex
A viable route to revenue
- Commercial readiness assessment
- Route to market — direct, distributor or hybrid
- Hospital procurement, GPOs and tenders
- Pricing that holds across both markets
- Provincial funding and market access
- KOL and clinical champion development
- Launch sequencing
- Commercial infrastructure and team
Revenue.Eight decisions, each of which can end the plan if it is guessed.
Apex is not primarily a regulatory consultancy and does not author submissions. Where an engagement requires regulatory, quality or formal reimbursement work, Apex contracts senior specialists for those workstreams and coordinates them — so the regulatory timeline serves the launch plan instead of colliding with it.
The commercial layer, in order
Eight decisions, and the order matters as much as the answers.
Commercial readiness
"Are we actually ready to enter, or just cleared?"
Evidence, pricing logic, reference customers, support model and organisational capacity assessed before spend is committed. This is where a go/no-go is cheapest.
Route to market
"Direct, distributor, or both?"
Modelled on economics rather than preference — margin stack, coverage, control of the clinical relationship, and what it costs to unwind if wrong. In Canada the answer is frequently different from the US answer for the same product.
Channel and distributor economics
"What does this actually pay at real volume?"
Distributor margin, minimum viable volume, exclusivity terms and performance conditions — built as a model you keep, not a slide.
Hospital procurement
"Who has to say yes before a clinician can use it?"
Value-analysis committees, group purchasing organisations, tender cycles and standardisation contracts. In Canada this is where most foreign entrants first discover the market is not what they modelled.
Pricing
"What number survives review — without breaking our other market?"
Price set against procurement reality and defended with an economic argument, sequenced so a Canadian reference price does not undermine US positioning.
Funding and market access
"Who pays, and out of which budget?"
Provincial funding envelopes, hospital global budgets and coverage pathways mapped per market. Formal reimbursement dossiers and HTA submissions are contracted to specialists where required.
Clinical champions
"Who argues for this when we are not in the room?"
Identification and development of the clinicians whose opinion moves a committee — influence-based rather than publication-count-based, and compliant by design.
Launch sequencing and infrastructure
"What do we build, when, and with whom?"
Which market first, what the commercial team looks like at each stage, and the milestones that justify the next tranche of spend.
The border
Canada isn't a smaller United States.
Same continent, same language, largely the same technology — and a commercial model that behaves differently at almost every decision point. Companies that treat Canada as a US rollout with a licence attached generally spend a year finding out.
Entering Canada
Concentrated, procedural, unforgiving of channel mistakes
- Buying
- Group purchasing and provincial procurement carry disproportionate weight. A single tender outcome can define a category for years.
- Funding
- Thirteen provincial and territorial systems, not one national payer. Budget holders differ by province and by care setting.
- Scale
- Volumes rarely justify a full direct organisation early — which makes the distributor decision consequential and difficult to reverse.
- Clinical community
- Small, interconnected and long-memoried. A poor early reference travels.
Entering the United States
Larger, faster, and more expensive to get wrong
- Buying
- IDNs, value-analysis committees and contracted GPO relationships. Access is won account by account.
- Funding
- Coding, coverage and payment need to be understood before pricing, not after.
- Scale
- Direct commercial build is viable sooner, and the cost of a mis-sized sales organisation is severe.
- Sequencing
- What you agree in Canada can constrain what you can charge in the US. The order is a decision, not an accident.
Where this comes from
Learned from inside operating companies, not from advisory theory.
Apex's market-entry work is grounded in having done it as an employee with a number to hit, in three different companies, before advising anyone on it.
Operating roles inside multinational and emerging medical-technology companies, described here by scope and category rather than by name. They are not Apex clients and no endorsement is implied.
Entering a market, or already in one that isn't working?
Tell us the product, the market and where it is stalling. Thirty minutes is usually enough to tell whether the problem is the channel, the price or the access.